Ergebnis der Suchanfrage nach @suche@B&ampoumlblingen

Heidelberg Materials AG

EANS-General Meeting: HeidelbergCement AG / Announcement convening the general meeting

Further inquiry note: Andreas Schaller +49 (0)6221/481-249 andreas.schaller@heidelbergcement.com Branche: Construction & Property ISIN: DE0006047004 WKN: 604700 Index: Midcap Market Index, MDAX, CDAX, Classic All Share, HDAX, Prime All Share Börsen: Frankfurt / regulated dealing/prime standard Berlin / free trade Hamburg / free trade Hannover / free trade Stuttgart ...

Boehringer Ingelheim

Boehringer Ingelheim Initiates First Phase III Clinical Trial in Ovarian Cancer

Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late-stage oncology pipeline compounds for the treatment of patients with advanced ovarian cancer. The clinical study, called LUME-Ovar-1 trial, investigates the compound BIBF 1120, a novel oral anti-angiogenic agent[1], ...

ElringKlinger AG

EANS-News: IAA 2009: ElringKlinger focuses on engine downsizing and CO2 reduction

Further inquiry note: For further information, please contact: ElringKlinger AG Corporate Communications Max-Eyth-Straße 2, 72581 Dettingen / Erms Phone: +49 (0)7123-724-640 / 137 Fax: +49 (0)7123-724-641 E-mail: stephan.haas@elringklinger.de karl-heinz.app@elringklinger.de Branche: Automotive Equipment ISIN: DE0007856023 WKN: 785602 Index: MDAX, Classic All Share, ...

Boehringer Ingelheim

New Data From Boehringer Ingelheim's Ongoing Linagliptin Trial Programme Show Promising Safety and Efficacy Results

Ingelheim, Germany (ots/PRNewswire) - - Results From Linagliptin Study in Type 2 Diabetes Patients Who Were Inadequately Controlled on Metformin Therapy Alone, Presented at Major Diabetes Meeting Study results presented for the first time in the scientific sessions of this year's American Diabetes Association Annual ...

K+S Aktiengesellschaft

EANS-News: K+S Aktiengesellschaft / Financing the acquisition of Morton Salt K+S successfully arranges EUR 1.55 billion of Credit Facilities

K+S Aktiengesellschaft / Financing the acquisition of Morton Salt K+S successfully arranges € 1.55 billion of Credit Facilities Further inquiry note: Your contact persons: Press: Investor Relations: Michael Wudonig Christian Herrmann Phone: +49 561 9301-1262 Phone: +49 561 9301-1460 Fax: +49 561 9301-1666 Fax: ...

OVB Holding AG

EANS-Voting Rights: OVB Holding AG / Release of a voting rights announcement according to article 26, section 1.1 WpHG (Securities Trading Act) with the aim of a Europe-wide distribution

Further inquiry note: Branche: Financial & Business Services ISIN: DE0006286560 WKN: 628656 Index: CDAX, Classic All Share, Prime All Share Börsen: Frankfurt / regulated dealing/prime standard Berlin / free trade Hamburg / free trade Stuttgart / free trade Düsseldorf / free trade München / free trade ...

Boehringer Ingelheim

No Increased Risk of Treatment-Induced Augmentation in Restless Legs Syndrome (RLS) Demonstrated in Long-Term Placebo-Controlled Study With Mirapexin(R) / Sifrol(R) (Pramipexole)

Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media outside the U.S.A. New data presented today at the 61st Annual Meeting of the American Academy of Neurology (AAN), in Seattle, U.S.A. show that augmentation did not significantly differ in RLS patients treated with Mirapexin(R) /Sifrol(R) (pramipexole*) ...

Vienna Insurance Group

EANS-News: Wiener Städtische Versicherung AG Vienna Insurance Group / Dividend Announcement and Share Repurchase

ISIN-Code: AT0000908504 Further inquiry note: VIENNA INSURANCE GROUP (V.I.G.) 1010 Wien, Schottenring 30 Mag. Barbara Hagen-Grötschnig Unternehmenskommunikation Tel.: +43 (0)50 350-21027 Fax: +43 (0)50 350 99-21027 E-Mail: barbara.hagen@vig.com Mag. Thomas Schmee Investor Relations Tel.: +43 (0)50 350-21900 Fax: ...

Vienna Insurance Group

EANS-Adhoc: Vienna Insurance Group / Vienna Insurance Group in 2008 in accordance with IFRS: Good results for 2008 confirmed

Further inquiry note: VIENNA INSURANCE GROUP (V.I.G.) 1010 Wien, Schottenring 30 Mag. Barbara Hagen-Grötschnig Unternehmenskommunikation Tel.: +43 (0)50 350-21027 Fax: +43 (0)50 350 99-21027 E-Mail: barbara.hagen@vig.com Mag. Thomas Schmee Investor Relations Tel.: +43 (0)50 350-21900 Fax: +43 (0)50 350 99-21900 ...

Boehringer Ingelheim

Experts Unite to Create New Online Resource for Restless Legs Syndrome

Ingelheim, Germany (ots/PRNewswire) - - Unique Educational Website 'Under the Covers of Restless Legs Syndrome (RLS)' is Launched on World Sleep Day - For Non-US Healthcare Media The website http://www.rlsunderthecovers.com brings together leading medical experts in the field of Restless Legs Syndrome (RLS) who have undertaken to explain key facts and symptoms of this ...

Semperit AG Holding

euro adhoc: Semperit AG Holding / Release according to article 93 BörseG with the aim of a Europe-wide distribution

Further inquiry note: Branche: Synthetics & Plastics ISIN: AT0000785555 WKN: 870378 Index: WBI, ATX Prime, ViDX Börsen: Börse Frankfurt / stock market Börse Stuttgart / stock market Börse Berlin / free trade Wiener Börse AG / official market ...

intec GmbH

New Handheld Tester ARGUS 145 plus: every DSL standard, Ethernet, ISDN and POTS in a single tester

C-QUADRAT Investment AG

C-QUADRAT Investment AG: General meeting approves share buy-back programme

Further inquiry note: Andreas Wimmer Member of the Board C-QUADRAT Investment AG Stubenring 2 A-1010 Wien Tel.: +43 1 515 66 316 Mail: a.wimmer@investmentfonds.at www.c-quadrat.com Branche: Financial & Business Services ISIN: AT0000613005 WKN: Index: Prime.market Börsen: Börse Frankfurt / official market Wiener Börse AG / official market ...

Boehringer Ingelheim

Telmisartan (MICARDIS(R)) as Effective as Ramipril But With Better Long-Term Tolerability in High-Risk Cardiovascular Asian Patients

Beijing (ots/PRNewswire) - New results from the landmark ONTARGET(R) Trial show that, in Asian patients at high risk of cardiovascular disease (CVD), telmisartan (MICARDIS(R)) 80mg is as effective as, and significantly better tolerated than, ramipril 10mg in reducing the risk of cardiovascular death, heart attack, ...

Lenzing AG

euro adhoc: Lenzing AG / Release according to article 93 BörseG with the aim of a Europe-wide distribution

Further inquiry note: Branche: Chemicals ISIN: AT0000644505 WKN: 852927 Index: WBI Börsen: Börse Berlin / free trade Wiener Börse AG / official dealing ...

Boehringer Ingelheim

MICARDIS(R)- Based Regimens Help More Patients Achieve Their Blood Pressure Goals

Berlin (ots/PRNewswire) - - For non-US Healthcare Media and non-UK Healthcare Media - New Studies Show Benefits of MICARDIS(R) (Telmisartan) in Combination With Amlodipine and Hydrochlorothiazide The results of two new studies of MICARDIS(R) (telmisartan) in free combination with amlodipine or fixed combination with hydrochlorothiazide (HCTZ) 25 mg confirm that a ...

Lenzing AG

euro adhoc: Lenzing AG / Annual & Special Corporate Meetings / Lenzing general shareholders´ meeting approves dividend of EUR 14.00 per share New chairman of the supervisory board Hermann Bell

Further inquiry note: Lenzing AG Mag. Angelika Guldt Tel.: +43 (0) 7672-701-2713 Fax: +43 (0) 07672-96301 mailto:a.guldt@lenzing.com Branche: Chemicals ISIN: AT0000644505 WKN: 852927 Index: WBI Börsen: Börse Berlin / free trade Wiener Börse AG / official dealing ...

Boehringer Ingelheim

New Data Shows Pramipexole (Mirapexin(R)/Sifrol(R)) Can Significantly Reduce Limb Pain in Patients With Restless Legs Syndrome (RLS)

Ingelheim, Germany (ots/PRNewswire) - - First Ever Study to Demonstrate Efficacy of Pramipexole in Treating RLS-Associated Limb Pain - For Healthcare Media Outside the U.S.A. A new study demonstrating that pramipexole (Mirapexin(R)/Sifrol(R)) can significantly reduce RLS-associated limb pain in patients with ...

United Internet AG

euro adhoc: United Internet AG / Release of a voting rights announcement according to article 26, section 1.1 WpHG (Securities Trading Act) with the aim of a Europe-wide distribution

Further inquiry note: Branche: Telecommunications Services ISIN: DE0005089031 WKN: 508903 Index: Midcap Market Index, TecDAX, CDAX, HDAX, Prime All Share, Technologie All Share Börsen: Börse Frankfurt / regulated dealing/prime standard Börse Berlin / free trade Börse Hamburg / free trade Börse Stuttgart / ...

OMV Aktiengesellschaft

OMV: Convocation of the Annual General Meeting

May 14, 2008, at 2:00 pm (CET), at the AUSTRIA CENTER VIENNA, in Bruno-Kreisky-Platz 1, 1220 Vienna, Austria Further inquiry note: OMV Investor Relations: Ana-Barbara Kuncic Tel. +43 1 40 440-21443; e-mail: investor.relations@omv.com Press: Bettina Gneisz-Al-Ani Tel. +43 1 40 440-21660; e-mail: bettina.gneisz@omv.com Thomas Huemer Tel. +43 1 40 440-21660; e-mail: thomas.huemer@omv.com Internet Homepage: ...

Boehringer Ingelheim

New Data Confirm Pramipexole (Mirapexin(R)/Sifrol(R)) Can Significantly Reduce Sleep Disturbance for People With Restless Legs Syndrome (RLS)

Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media Outside the U.S.A. - Studies Demonstrate Positive and Rapid Impact of Pramipexole on the Core Symptoms of Restless Legs Syndrome and Sleep Disturbance A new study has shown that pramipexole (Mirapexin(R)/Sifrol(R)) can significantly reduce sleep ...

Vienna Insurance Group

Wiener Städtische Versicherung AG Vienna Insurance Group: Dividend / Share Repurchase

Further inquiry note: Mag. Barbara Hagen-Grötschnig Unternehmenskommunikation WIENER STÄDTISCHE Versicherung AG Vienna Insurance Group A-1010 Wien, Schottenring 30 Tel.: +43 (0)50 350-21027 Fax: +43 (0)50 350 99-21027 E-Mail: b.hagen@staedtische.co.at Branche: Insurance ISIN: AT0000908504 WKN: A0ET17 Index: WBI, ATX Prime, ATX Börsen: Prague Stock Exchange / stock ...

Boehringer Ingelheim

New Powerful Antihypertensive MicardisPlus(R) 80/25 (80mg telmisartan/25mg hydrochlorothiazide) Approved by EU Commission

Ingelheim, Germany (ots/PRNewswire) - - For Medical Media, Outside the US Only Boehringer Ingelheim today announced that the European Commission has granted marketing authorisation of the new powerful strength of their fixed dose combination antihypertensive drug MicardisPlus(R) 80/25 in all 27 EU member states. It ...

Vienna Insurance Group

euro adhoc: Vienna Insurance Group / other / Vienna Insurance Group raises Group Embedded Value to more than EUR 4.5 billion

Further inquiry note: Contact: WIENER STÄDTISCHE Versicherung AG Vienna Insurance Group Barbara Hagen-Grötschnig, MBA Corporate Communications Schottenring 30, 1010 Vienna Tel.: +43 (0)50 350-21027 Fax: +43 (0)50 350 99-21027 E-Mail: b.hagen@staedtische.co.at Branche: Insurance ISIN: AT0000908504 WKN: A0ET17 ...